Help protect 2 populations at risk of RSV with 1 vaccine 2
INFANTS via maternal immunisation 1, 2
RSV is a leading cause of hospitalisation due to LRTDs, such as bronchiolitis and pneumonia, in infants under 6 months old. 3, 4
ADULTS aged ≥60 years 1, 2
Older adults § hospitalised with RSV are more likely to have longer hospital stays compared with younger individuals. 3
LRTD, lower respiratory tract disease. §
Adults aged ≥65 years. 3
ABRYSVO helps protect against RSV-LRTD in infants from birth to 6 months, and in adults aged ≥60 years across two RSV seasons 5 – 8
Phase 3 MATISSE study 5, 6
Vaccine efficacy against severe MA RSV-LRTD
Phase 3 RENOIR study 1, 7, 8
Vaccine efficacy against RSV-LRTD with ≥3 symptoms
At
82 % 3 months
89 %
95 % CI: 57.5, 93.9
Across
Season 1
95 % CI: 53.6, 98.7 Mean follow-up: 7.05 months
70 % |
|
|
|
At
6 months
95 % CI: 50.6, 82.5
|
78 % |
|
Across
Season 2
95 % CI: 51.4, 91.1 Total mean follow-up: 17.6 months
|
MA, medically attended; RSV-LRTD, RSV-associated LRTD.
No safety concerns have been identified in Phase 3 studies evaluating ABRYSVO in pregnant women, infants and older adults. ¶ 5 – 7
¶
In Phase 3 studies, no adverse events leading to study withdrawal were reported in pregnant women( n = 3,698) or adults aged ≥60 years( n = 17,215) who received ABRYSVO. No safety signals were detected in infants to 2 years after birth. 5 – 7
ABRYSVO can be given: 2
Year-round
Co-administered with certain other vaccines
Pregnant women( ABRYSVO only)
Between 28 – 36 weeks gestation, regardless of expected delivery date
At the same time, or separately to dTpa, influenza and COVID-19
Adults aged ≥60 years( ABRYSVO or Arexvy)
But should be offered before the start of the RSV season, where possible
Including influenza, COVID-19, zoster and pneumococcal
MATISSE study primary efficacy endpoints: vaccine efficacy within 90, 120, 150 and 180 days after birth, against: 1) Severe MA RSV-LRTD, and 2) MA RSV-LRTD. 5, 6
RENOIR study primary efficacy endpoints: vaccine efficacy through Season 1 against RSV-LRTD with: ≥2 symptoms, or ≥3 symptoms( including cough, wheezing, sputum production, shortness of breath and tachypnoea); analysis continued through Season 2 to assess duration of protection. 7, 8
References: 1. ABRYSVO Approved Product Information. 2. Australian Immunisation Handbook. Respiratory syncytial virus( RSV). Available at: https:// immunisationhandbook. health. gov. au / contents / vaccine-preventable-diseases / respiratory-syncytial-virus-rsv. Accessed February 2025. 3. Saravanos GL, et al. Med J Aust. 2019; 210:447 – 453. 4. Self A, et al. BMC Public Health. 2023; 23:2560. 5. Kampmann B, et al. N Engl J Med. 2023; 388:1451 – 1464. 6. Simões EAF, et al. Obstet Gynecol. 2025; 145:157 – 167. 7. Walsh EE, et al. N Engl J Med. 2023; 388:1465 – 1477. 8. Walsh EE, et al. N Engl J Med. 2024; 391:1459 – 1460. Abrysvo ® is a registered trademark. Pfizer Australia Pty Limited, Sydney, Australia. www. pfizer. com. au. Pfizer Medical Information: 1800 675 229. PP-A1G-AUS-0268. ABR-003335-01. February 2025.